Aurobindo Pharma subsidiary acquires Khandelwal Laboratories’ non-oncology prescription business for ₹325 cr

Aurobindo Pharma Ltd's wholly-owned subsidiary, Auro Pharma Ltd, on Thursday, January 1, announced the acquisition of the branded non-oncology prescription formulations business of Khandelwal Laboratories Private Ltd on a going concern basis.

The company's exchange filing stated that the acquisition was completed through a Business Transfer Agreement (BTA) and is effective from January 1, 2026.

The acquired business includes 23 brands marketed across 67 SKUs and nine pipeline products, with major portfolios in anti-infective and pain management. The business employs around 470 field staff and has a distribution network comprising over 1,600 stockists and related infrastructure. In FY2024-25, the business recorded a turnover of ₹1,135.3 million with an EBITDA of ₹289.9 million, according to the exchange filing.

Founded in 1973-74, Khandelwal Laboratories operates in India and specialises in branded oncology and non-oncology prescription formulations. The acquisition will help Auro Pharma strengthen its presence in the domestic pharmaceutical market and complement its existing product portfolio in pain management and anti-infective segments.

The transaction, valued at ₹3,250 million in cash (subject to working capital adjustments), does not involve the acquisition of any shares or control of Khandelwal Laboratories.

Auro Pharma’s managing team said the acquisition will enhance the company’s growth prospects and provide a wider range of prescription offerings to the domestic market.

Shares of Aurobindo Pharma Ltd ended higher on Thursday, January 1, by 1.18% at ₹1,197.00 on the NSE.

Also Read: Aurobindo Pharma shares little changed after unit CuraTeQ terminates agreement with BioFactura